Impact of Ibis, a Digital Health Solution for Patient Activation and Early Intervention, on Acute Care Utilization by Patients With Advanced COPD
| Registry | NCT03131622 |
|---|---|
| Status | Unknown |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: none, supportive care |
| Enrollment | 240 (Estimated) |
| Sponsor | Senscio Systems (Industry); collaborators: Central Maine Medical Family |
| Conditions | COPD |
| Interventions | Digital Therapeutics (Behavioral) |
| Dates | start 2016-12-01, primary completion 2018-01-01 (estimated), completion 2018-01-01 (estimated), first posted 2017-04-27, last updated 2017-04-27 |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for COPD All trials of Digital Therapeutics
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients with COPD.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Digital Therapeutics | Experimental | Behavioral: Digital Therapeutics | Patients assigned to the digital therapeutics arm will receive Ibis and all the associate services. |
| Control | No intervention |
Sex: All
Inclusion Criteria: * Gold Stage II with a CAT Score above 19 * Gold Stage III/IV with a CAT Score above 14 Exclusion Criteria: * Cognitive or physical impediments that inhibits patients from interacting with our digital therapeutics platform.